CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis AG v. HEC Pharm Co. Ltd.

1:15-cv-00151

Overview

Case Number 1:15-cv-00151
Filing Date 2015-02-11
Status Terminated
Termination Date 2017-06-09
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:0145
Jury Demand None

Parties

Defendant

HEC Pharm USA Inc. Operating Company

Represented By

4 Attorneys Listed

Yongjin Zhu

Email: yongjin.zhu@haynesboone.com

C. Kyle Musgrove

Email: kylemusgrove@parkerpoe.com

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

Jacqueline Lu

Email: JLu@dickinson-wright.com

HEC Pharm Co. Ltd. Operating Company

Represented By

7 Attorneys Listed

Yongjin Zhu

Email: yongjin.zhu@haynesboone.com

Yifang Zhao

Email: eva.zhao@haynesboone.com

James Shimota

Email: jim.shimota@haynesboone.com

C. Kyle Musgrove

Email: kylemusgrove@parkerpoe.com

Brian Kwok

Email: brian.kwok@haynesboone.com

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

Jacqueline Lu

Email: JLu@dickinson-wright.com

Mitsubishi Tanabe Pharma Corporation NPE (University / Research)

Represented By

4 Attorneys Listed

Nao Takada

UNDELIVERABLE EMAIL 11/8/2017

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis AG Operating Company

Represented By

13 Attorneys Listed

Robert W. Trenchard

Email: rtrenchard@gibsondunn.com

Paul J. Kremer

Email: pkremer@gibsondunn.com

Nao Takada

UNDELIVERABLE EMAIL 11/8/2017

Michael A. Valek

Email: mvalek@gibsondunn.com

Jane M. Love

Email: jlove@gibsondunn.com

Beatrice Hahn

UNDELIVERABLE EMAIL 12/10/18

Barish Ozdamar

Email: Barish.Ozdamar@wilmerhale.com

Andrew Blythe

Email: ablythe@gibsondunn.com

Alexander N. Harris

Email: aharris@gibsondunn.com

Caitlin R. Looby

Email: caitlin.looby@wilmerhale.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

5 Attorneys Listed

Nao Takada

UNDELIVERABLE EMAIL 11/8/2017

Alexander N. Harris

Email: aharris@gibsondunn.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Plaintiff

Mitsui Sugar Co. Ltd. NPE (University / Research)

Represented By

4 Attorneys Listed

Nao Takada

UNDELIVERABLE EMAIL 11/8/2017

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Counter Claimant

HEC Pharm Group Operating Company

Represented By

4 Attorneys Listed

Aya Cieslak-Tochigi

Email: atochigi@farneydaniels.com

Steven R Daniels

Email: sdaniels@dickinsonwright.com

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

Michael Siem

Email: msiem@devlinlawfirm.com

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 7 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 2 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (7): 🇯🇵 Japan 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (2 found):
PTAB: 2
USPTO PTAB Trial 2014-12-31
IPR2015-00518

Apotex, Inc. et al. v. Novartis AG et al.

U.S. Continuation Sibling (8324283)
Status: Final Written Decision
USPTO PTAB Trial 2014-05-27
IPR2014-00784

TORRENT PHARMACEUTICALS LIMITED v. Novartis AG et al.

U.S. Continuation Sibling (8324283)
Status: Final Written Decision
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5604229
2-amino-1,3-propanediol compound and immunosuppressant
Filed: 1993-10-18
Issued: 1997-02-18
Expired (Term Ended) +1949d PTA
Expires: 2019-02-18
US8324283
Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Filed: 2008-08-11
Issued: 2012-12-04
Expired (Term Ended)
Expires: 2026-03-29

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1949 days) / Cellect Scrutiny — Over 1949 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

70

Dispositive

54

Granted

0

Denied

4

Pending / Review

56

Motions by Category

Motion to Dismiss 46 Claim Construction / Markman Filing 5 Procedural / Extension Motion 7 Motion to Stay Pending IPR / Reexam 7 Motion to Stay 4 Motion for Summary Judgment (Rule 56) 1

Key Dispositive Motions & Rulings

Motion for Summary Judgment (Rule 56) Denied
MEMORANDUM ORDER re (209 in 1:14-cv-01487-LPS) MOTION for Summary Judgment is DENIED as moot; (216 in 1:14-cv-01487-LPS) MOTION to Preclude is DENIED as moot; (...
Entry #215 • 2017-04-17 Document →
Motion to Dismiss Granted in Part
ORDER re (209 in 1:15-cv-00150-LPS, 230 in 1:14-cv-01487-LPS, 207 in 1:15-cv-00151-LPS, 126 in 1:15-cv-00975-LPS) Memorandum Opinion -- (151 in 1:14-cv-01487-LP...
Entry #208 • 2017-03-17 Document →
Motion to Dismiss Pending / Under Review
ORDER re 194 MOTION to Dismiss Certain Counterclaims filed by HEC Pharm Co. Ltd. Signed by Judge Leonard P. Stark on 11/10/16. (ntl) (Entered: 11/10/2016)
Entry #195 • 2016-11-10 Document →
Motion to Dismiss Pending / Under Review
MOTION to Dismiss Based upon Unopposed Dismissal of Certain Counterclaims - filed by HEC Pharm Co. Ltd.. (Stamoulis, Stamatios) (Entered: 11/08/2016)
Entry #194 • 2016-11-08 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of 189 Reply Brief, re 180 MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novarti...
Entry #192 • 2016-09-09 Document →
Motion to Dismiss Pending / Under Review
[SEALED] REPLY BRIEF re 180 MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of...
Entry #189 • 2016-09-02 Document →

Docket Entries

(341 total)
Pleading / Complaint

COMPLAINT filed against HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1673590.) - filed by Novartis AG, Mitsui Sugar Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(etg, ) (Entered: 02/12/2015)

Entry #1 • 2015-02-11
1
Pleading / Complaint

COMPLAINT filed against HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1673590.) - filed by Novartis AG, Mitsui Sugar Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(etg, ) (Entered: 02/12/2015)

Entry #1 • 2015-02-11
2
Pleading / Complaint

COMPLAINT filed against HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1673590.) - filed by Novartis AG, Mitsui Sugar Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(etg, ) (Entered: 02/12/2015)

Entry #1 • 2015-02-11
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (etg, ) (Entered: 02/12/2015)

Entry #2 • 2015-02-11
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 01/19/15. Date of Expiration of Patent: 02/18/19.Thirty Month Stay Deadline: 3/21/2018. (etg, ) (Entered: 02/12/2015)

Entry #3 • 2015-02-11
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc